Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor

Wilex/4SC: cancer research collaboration should bear fruit

The German biotech companies aim to accelerate the development of products related to Wilex's lead compound WX-293. Both companies should benefit from the deal: Wilex will gain access to the latest targeted drug development technologies, while 4SC will directly increase its revenues through milestone payments.

Published By Datamonitor

Vinka alkaloids: market to fall 17% by 2007

Published By Datamonitor

Vascular dementia: drug sales will rapidly proliferate

Published By Datamonitor

Unstable angina: incidences to grow 0.6% per year

Published By Datamonitor

UK pharmaceuticals: potential pricing safe haven

With healthcare reform and cost containment initiatives taking hold throughout Europe, the UK is becoming increasingly attractive to the branded pharmaceutical sector. Through price control deregulation the UK government could attract increased investment, but it must be careful to balance the interests of patients with those of the industry.<BR />

Published By Datamonitor

UCB: continuing the European Mid-Pharma consolidation craze

Having enjoyed past success from acquisitions, Belgian-based UCB is now looking to Schwarz Pharma, with its impressive late-stage pipeline, to boost its growth potential. This merger agreement is the latest in a recent 'acquisition frenzy', and highlights the current trend towards consolidation in the European pharmaceutical sector.

Published By Datamonitor

UCB/Schwarz: a leading CNS proposition moves a step closer

The $5.5 billion takeover of Schwarz Pharma by Belgian rival UCB looks likely to go ahead, as preliminary figures show that UCB has received tenders in excess of 76% of the share capital of Schwarz Pharma. In addition to generating significant synergies, the deal is expected to create a leading neurology-focused pharmaceuticals group.

Published By Datamonitor

Traumatic brain injuries: numbers will rise in US, fall in Germany and Italy

Published By Datamonitor

TeGenero: bankruptcy beckons

German biotech firm TeGenero has filed for bankruptcy just four months after a catastrophic safety trial with its immunomodulatory drug candidate TGN1412 left six healthy volunteers fighting for their lives. However, this does not necessarily signal the end for TGN1412, which may still have a future if anyone is brave enough to take it on for further research.

Published By Datamonitor